Suchergebnisse - "Boeree, Martin J"

PubPharm (186)

1

High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: evidence for heteroresistance

enthalten in: bioRxiv.org | 2024

von Martinecz, A. | Boeree, M. | Diacon, A. | +4

2

Clofazimine Is a Safe and Effective Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment : Outcomes of a Randomized Trial

enthalten in: Chest | 2023

von Zweijpfenning, S. | Aarnoutse, R. | Boeree, M. | +5

3

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis

enthalten in: Antimicrobial agents and chemotherapy | 2023

von Stemkens, R. | Jager, V. | Dawson, R. | +13

4

Phase 2b Open-label Randomized Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of N-acetylcysteine in Reducing Adverse Drug Reactions among Adults Treated for Multidrug-resistant Tuberculosis in Tanzania. (Trial Acronym NAC Trial).

enthalten in: ResearchSquare.com | 2023

von Mpagama, S. | Mvungi, H. | Mbelele, P. | +8

5

Treatment Strategy for Rifampin-Susceptible Tuberculosis

enthalten in: The New England journal of medicine | 2023

von Boeree, M. | Heinrich, N. | Aarnoutse, R.

CommentOn: N Engl J Med. 2023 Mar 9;388(10):873-887. - PMID 36808186

6

Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin

enthalten in: International journal of antimicrobial agents | 2023

von Susanto, B. | Svensson, E. | Te Brake, L. | +4

7

High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients : Evidence for heteroresistance

enthalten in: PLoS computational biology | 2023

von Martinecz, A. | Boeree, M. | Diacon, A. | +4

8

Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis : a 2023 TBnet/RESIST-TB consensus statement

enthalten in: The Lancet. Infectious diseases | 2023

von Domínguez, J. | Boeree, M. | Cambau, E. | +54

ErratumIn: Lancet Infect Dis. 2023 Mar 28;:. - PMID 37001542

9

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development

enthalten in: Frontiers in pharmacology | 2023

von Ayoun Alsoud, R. | Svensson, R. | Svensson, E. | +6

10

New and Repurposed Drugs for the Treatment of Active Tuberculosis : An Update for Clinicians

enthalten in: Respiration; international review of thoracic diseases | 2023

von Aguilar Diaz, J. | Abulfathi, A. | Te Brake, L. | +6

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[19]